0855313 Search Results


  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93
    Valiant human albumin
    Human Albumin, supplied by Valiant, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human albumin/product/Valiant
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    human albumin - by Bioz Stars, 2021-05
    93/100 stars
      Buy from Supplier

    igg  (Valiant)
    91
    Valiant igg
    Igg, supplied by Valiant, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/igg/product/Valiant
    Average 91 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    igg - by Bioz Stars, 2021-05
    91/100 stars
      Buy from Supplier

    94
    Valiant human immunoglobulin m
    Comparison of ibrutinib and acalabrutinib-mediated changes in the levels of Bcl-2 and Mcl-1 antiapoptotic proteins A. CLL cells were incubated with DMSO only (controls) or with 1 μM or 3 μM ibrutinib or acalabrutinib for 48 hours without <t>IgM</t> stimulation (lanes 1-5) or with IgM stimulation (lanes 6-10). The protein lysates were immunoblotted for total Bcl-2 and Mcl-1 proteins. Vinculin was used as a loading control. B-C. Immunoblots were analyzed from five different patients, and changes in Mcl-1 and Bcl-2 in CLL cells treated with BTK inhibitors without (B) or with (C) IgM stimulation were quantitated. Values represent fold change relative to DMSO controls.
    Human Immunoglobulin M, supplied by Valiant, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human immunoglobulin m/product/Valiant
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    human immunoglobulin m - by Bioz Stars, 2021-05
    94/100 stars
      Buy from Supplier

    94
    Valiant hamster immunoglobulin g
    NCoR1 binds to the Bim promoter and represses Bim expression. a RNA-Seq analysis of differentially expressed genes in NCoR1-deficient (cKO) and wild-type (WT) thymocytes with or without activation in vitro. b , c Quantitative RT-PCR analysis of Bim mRNA expression in freshly sorted cKO ( n = 6) and WT ( n = 6) CD4 + CD8 + double-positive (DP) thymocytes ( b ), and in total cKO ( n = 4) and WT ( n = 4) thymocytes ( c ) after in vitro TCR stimulation for the indicated amounts of time. d Immunoblot analysis of NCoR1 and Bim expression levels in extracts of cKO and WT thymocytes with or without stimulation for the indicated amounts of time. e Quantification of NCoR1 and Bim expression levels in ( d ). f ChIP analysis of the Bim promoter by anti-NCoR1 in cKO and WT thymocytes with or without activation in vitro. <t>IgG</t> served as a negative control. g ChIP analysis of the Bim promoter in cKO and WT thymocytes using the indicted antibodies. The data are representative of two independent experiments ( b , c , f , g ). Statistical significance was analyzed using the two-tailed Student’s t test (* P
    Hamster Immunoglobulin G, supplied by Valiant, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hamster immunoglobulin g/product/Valiant
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    hamster immunoglobulin g - by Bioz Stars, 2021-05
    94/100 stars
      Buy from Supplier

    Image Search Results


    Comparison of ibrutinib and acalabrutinib-mediated changes in the levels of Bcl-2 and Mcl-1 antiapoptotic proteins A. CLL cells were incubated with DMSO only (controls) or with 1 μM or 3 μM ibrutinib or acalabrutinib for 48 hours without IgM stimulation (lanes 1-5) or with IgM stimulation (lanes 6-10). The protein lysates were immunoblotted for total Bcl-2 and Mcl-1 proteins. Vinculin was used as a loading control. B-C. Immunoblots were analyzed from five different patients, and changes in Mcl-1 and Bcl-2 in CLL cells treated with BTK inhibitors without (B) or with (C) IgM stimulation were quantitated. Values represent fold change relative to DMSO controls.

    Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

    Article Title: Comparison of acalabrutinib, a selective Bruton tyrosine kinase inhibitor, with ibrutinib in chronic lymphocytic leukemia cells

    doi: 10.1158/1078-0432.CCR-16-1446

    Figure Lengend Snippet: Comparison of ibrutinib and acalabrutinib-mediated changes in the levels of Bcl-2 and Mcl-1 antiapoptotic proteins A. CLL cells were incubated with DMSO only (controls) or with 1 μM or 3 μM ibrutinib or acalabrutinib for 48 hours without IgM stimulation (lanes 1-5) or with IgM stimulation (lanes 6-10). The protein lysates were immunoblotted for total Bcl-2 and Mcl-1 proteins. Vinculin was used as a loading control. B-C. Immunoblots were analyzed from five different patients, and changes in Mcl-1 and Bcl-2 in CLL cells treated with BTK inhibitors without (B) or with (C) IgM stimulation were quantitated. Values represent fold change relative to DMSO controls.

    Article Snippet: BCR signaling was stimulated by incubating CLL cells with goat F(ab’)2 fragments of human immunoglobulin M (IgM; MP Biomedicals, Santa Ana, CA).

    Techniques: Incubation, Western Blot

    Cell death induced by ibrutinib and acalabrutinib was associated with PARP and caspase 3 cleavage A. Increase in PARP and caspase 3 cleavage after treatment with BTK inhibitors without IgM stimulation (lanes 1-5) and with IgM stimulation (lanes 6-10). Leukemic lymphocytes were treated with DMSO only (control) or with 1 μM or 3 μM ibrutinib or acalabrutinib for 48 hours with or without BCR pathway stimulation with IgM. The protein lysates were immunoblotted with total and cleaved PARP or caspase 3 antibodies as described in the Methods. Vinculin was used as a loading control. B and C. Immunoblots were analyzed for five patients, and cleaved PARP (B) and caspase 3 (C) bands were quantitated for CLL cells treated with BTK inhibitors without IgM stimulation. Values represent fold change relative to control.

    Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

    Article Title: Comparison of acalabrutinib, a selective Bruton tyrosine kinase inhibitor, with ibrutinib in chronic lymphocytic leukemia cells

    doi: 10.1158/1078-0432.CCR-16-1446

    Figure Lengend Snippet: Cell death induced by ibrutinib and acalabrutinib was associated with PARP and caspase 3 cleavage A. Increase in PARP and caspase 3 cleavage after treatment with BTK inhibitors without IgM stimulation (lanes 1-5) and with IgM stimulation (lanes 6-10). Leukemic lymphocytes were treated with DMSO only (control) or with 1 μM or 3 μM ibrutinib or acalabrutinib for 48 hours with or without BCR pathway stimulation with IgM. The protein lysates were immunoblotted with total and cleaved PARP or caspase 3 antibodies as described in the Methods. Vinculin was used as a loading control. B and C. Immunoblots were analyzed for five patients, and cleaved PARP (B) and caspase 3 (C) bands were quantitated for CLL cells treated with BTK inhibitors without IgM stimulation. Values represent fold change relative to control.

    Article Snippet: BCR signaling was stimulated by incubating CLL cells with goat F(ab’)2 fragments of human immunoglobulin M (IgM; MP Biomedicals, Santa Ana, CA).

    Techniques: Western Blot

    Comparison of ibrutinib and acalabrutinib-mediated inhibition of chemokine production and pseudoemperipolesis A-D. Effect of BTK inhibitors on CCL3 production and secretion from CLL cells. Freshly isolated CLL cells from four patients were either untreated ( A-B) or stimulated with IgM ( C-D ). Cells were treated with DMSO or 1 μM ibrutinib (IBT) or acalabrutinib (ACP) for 24 hours. CCL3 concentrations in media were measured by enzyme-linked immunosorbent assay as described in the Methods section. Statistical analyses were performed to compare ibrutinib with acalabrutinib without IgM (p = 0.355) or with IgM (p = 0.170). E-F. Effect of BTK inhibitors on CCL4 production and secretion from CLL cells. Freshly isolated CLL cells from four patients were either untreated ( E-F) or stimulated with IgM ( G-H ). Cells were treated with DMSO or 1 μM ibrutinib (IBT) or acalabrutinib (ACP) for 24 hours. CCL4 concentrations in media were measured by enzyme-linked immunosorbent assay as described in the Methods section. Statistical analyses were performed to compare ibrutinib with acalabrutinib without IgM (p = 0.246) or with IgM (p = 0.747). I. Impact of BTK inhibitors on pseudoemperipolesis. Primary CLL cells were treated with DMSO, acalabrutinib, or ibrutinib at different concentrations and placed on stromal cells for 4 hours. Cells were removed from the suspension. Cells that migrated under the stroma were counted. Values represent the percentage of cells that migrated relative to DMSO controls. Statistical analyses were performed to compare 1 μM ibrutinib with 1 μM acalabrutinib (p = 0.678) or 3 μM ibrutinib with 3 μM acalabrutinib (p = 0.887).

    Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

    Article Title: Comparison of acalabrutinib, a selective Bruton tyrosine kinase inhibitor, with ibrutinib in chronic lymphocytic leukemia cells

    doi: 10.1158/1078-0432.CCR-16-1446

    Figure Lengend Snippet: Comparison of ibrutinib and acalabrutinib-mediated inhibition of chemokine production and pseudoemperipolesis A-D. Effect of BTK inhibitors on CCL3 production and secretion from CLL cells. Freshly isolated CLL cells from four patients were either untreated ( A-B) or stimulated with IgM ( C-D ). Cells were treated with DMSO or 1 μM ibrutinib (IBT) or acalabrutinib (ACP) for 24 hours. CCL3 concentrations in media were measured by enzyme-linked immunosorbent assay as described in the Methods section. Statistical analyses were performed to compare ibrutinib with acalabrutinib without IgM (p = 0.355) or with IgM (p = 0.170). E-F. Effect of BTK inhibitors on CCL4 production and secretion from CLL cells. Freshly isolated CLL cells from four patients were either untreated ( E-F) or stimulated with IgM ( G-H ). Cells were treated with DMSO or 1 μM ibrutinib (IBT) or acalabrutinib (ACP) for 24 hours. CCL4 concentrations in media were measured by enzyme-linked immunosorbent assay as described in the Methods section. Statistical analyses were performed to compare ibrutinib with acalabrutinib without IgM (p = 0.246) or with IgM (p = 0.747). I. Impact of BTK inhibitors on pseudoemperipolesis. Primary CLL cells were treated with DMSO, acalabrutinib, or ibrutinib at different concentrations and placed on stromal cells for 4 hours. Cells were removed from the suspension. Cells that migrated under the stroma were counted. Values represent the percentage of cells that migrated relative to DMSO controls. Statistical analyses were performed to compare 1 μM ibrutinib with 1 μM acalabrutinib (p = 0.678) or 3 μM ibrutinib with 3 μM acalabrutinib (p = 0.887).

    Article Snippet: BCR signaling was stimulated by incubating CLL cells with goat F(ab’)2 fragments of human immunoglobulin M (IgM; MP Biomedicals, Santa Ana, CA).

    Techniques: Inhibition, Isolation, Enzyme-linked Immunosorbent Assay

    Comparison of ibrutinib- and acalabrutinib-mediated inhibition of BTK phosphorylation and downstream signaling A. CLL cells were incubated with DMSO only (controls) or with 1 μM or 3 μM ibrutinib or acalabrutinib for 48 hours without IgM stimulation (lanes 1-5) or with IgM stimulation (lanes 6-10). The protein lysates were immunoblotted for total and phosphorylated BTK, AKT, ERK, and S6 proteins. Vinculin was used as a loading control. B. Immunoblots representing five different patient samples without IgM stimulation were quantitated. Values represent fold change in phosphorylated protein relative to total protein.

    Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

    Article Title: Comparison of acalabrutinib, a selective Bruton tyrosine kinase inhibitor, with ibrutinib in chronic lymphocytic leukemia cells

    doi: 10.1158/1078-0432.CCR-16-1446

    Figure Lengend Snippet: Comparison of ibrutinib- and acalabrutinib-mediated inhibition of BTK phosphorylation and downstream signaling A. CLL cells were incubated with DMSO only (controls) or with 1 μM or 3 μM ibrutinib or acalabrutinib for 48 hours without IgM stimulation (lanes 1-5) or with IgM stimulation (lanes 6-10). The protein lysates were immunoblotted for total and phosphorylated BTK, AKT, ERK, and S6 proteins. Vinculin was used as a loading control. B. Immunoblots representing five different patient samples without IgM stimulation were quantitated. Values represent fold change in phosphorylated protein relative to total protein.

    Article Snippet: BCR signaling was stimulated by incubating CLL cells with goat F(ab’)2 fragments of human immunoglobulin M (IgM; MP Biomedicals, Santa Ana, CA).

    Techniques: Inhibition, Incubation, Western Blot

    NCoR1 binds to the Bim promoter and represses Bim expression. a RNA-Seq analysis of differentially expressed genes in NCoR1-deficient (cKO) and wild-type (WT) thymocytes with or without activation in vitro. b , c Quantitative RT-PCR analysis of Bim mRNA expression in freshly sorted cKO ( n = 6) and WT ( n = 6) CD4 + CD8 + double-positive (DP) thymocytes ( b ), and in total cKO ( n = 4) and WT ( n = 4) thymocytes ( c ) after in vitro TCR stimulation for the indicated amounts of time. d Immunoblot analysis of NCoR1 and Bim expression levels in extracts of cKO and WT thymocytes with or without stimulation for the indicated amounts of time. e Quantification of NCoR1 and Bim expression levels in ( d ). f ChIP analysis of the Bim promoter by anti-NCoR1 in cKO and WT thymocytes with or without activation in vitro. IgG served as a negative control. g ChIP analysis of the Bim promoter in cKO and WT thymocytes using the indicted antibodies. The data are representative of two independent experiments ( b , c , f , g ). Statistical significance was analyzed using the two-tailed Student’s t test (* P

    Journal: Nature Communications

    Article Title: NCoR1 restrains thymic negative selection by repressing Bim expression to spare thymocytes undergoing positive selection

    doi: 10.1038/s41467-017-00931-8

    Figure Lengend Snippet: NCoR1 binds to the Bim promoter and represses Bim expression. a RNA-Seq analysis of differentially expressed genes in NCoR1-deficient (cKO) and wild-type (WT) thymocytes with or without activation in vitro. b , c Quantitative RT-PCR analysis of Bim mRNA expression in freshly sorted cKO ( n = 6) and WT ( n = 6) CD4 + CD8 + double-positive (DP) thymocytes ( b ), and in total cKO ( n = 4) and WT ( n = 4) thymocytes ( c ) after in vitro TCR stimulation for the indicated amounts of time. d Immunoblot analysis of NCoR1 and Bim expression levels in extracts of cKO and WT thymocytes with or without stimulation for the indicated amounts of time. e Quantification of NCoR1 and Bim expression levels in ( d ). f ChIP analysis of the Bim promoter by anti-NCoR1 in cKO and WT thymocytes with or without activation in vitro. IgG served as a negative control. g ChIP analysis of the Bim promoter in cKO and WT thymocytes using the indicted antibodies. The data are representative of two independent experiments ( b , c , f , g ). Statistical significance was analyzed using the two-tailed Student’s t test (* P

    Article Snippet: After crosslinking with goat antibody to hamster immunoglobulin G (20 μg ml−1 ; 55397; MP Biomedicals) at various time points, the cells were lysed and subjected to SDS-PAGE.

    Techniques: Expressing, RNA Sequencing Assay, Activation Assay, In Vitro, Quantitative RT-PCR, Chromatin Immunoprecipitation, Negative Control, Two Tailed Test